Drug Profile
Escherichia coli vaccine - AstraZeneca
Alternative Names: MEDI 516; Urinary tract infections vaccine - AstraZeneca; UTI vaccine - AstraZenecaLatest Information Update: 20 Oct 2021
Price :
$50
*
At a glance
- Originator Washington University
- Developer Chiron Corporation; Washington University
- Class Escherichia coli vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Urinary tract infections
Most Recent Events
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 31 Dec 2002 Discontinued - Phase-II for Urinary tract infections in USA (IM)
- 21 Mar 2001 MedImmune has initiated a second phase II trial of its UTI vaccine